Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 233 Ayer Road Suite 4, Suite 4 HARVARD MA 01451 |
Tel: | N/A |
Website: | https://aquabounty.com |
IR: | See website |
Key People | ||
Sylvia A. Wulf Chairman of the Board, Chief Executive Officer | David F. Melbourne President | David A. Frank Chief Financial Officer, Treasurer | Angela M. Olsen General Counsel, Corporate Secretary |
Business Overview |
AquaBounty Technologies, Inc. is a land-based aquaculture company. The Company provides fresh Atlantic salmon to nearby markets by raising its fish in monitored land-based fish farms. The Company's land-based Recirculating Aquaculture System (RAS) farms are designed to prevent disease and include multiple levels of fish containment to protect wild fish populations. RAS facilities provide water treatment technology, including the use of ozone, salt treatment and ultraviolet radiation to kill potential bacterial, fungal, or viral pathogens, which might enter the system. Its GE Atlantic salmon is based upon salmon genetics and grows to harvest size faster than conventional Atlantic salmon. The Company is vertically integrated and maintains its own broodstock hatchery, which produces the eggs that it grows-out to harvest size in its production farms. It operates two salmon farms: a 1,200 metric ton production grow-out farm in Indiana and a broodstock farm on Prince Edward Island, Canada. |
Financial Overview |
For the nine months ended 30 September 2023, Aquabounty Technologies Inc revenues decreased 29% to $1.9M. Net loss increased 19% to $19.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects General and administrative increase of 12% to $8.4M (expense), Other Income (expense), Net decrease of 82% to $62K (income). |
Employees: | 100 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $2.37M as of Sep 30, 2023 |
EBITDA (TTM): | -$22.98M as of Sep 30, 2023 |
Net annual income (TTM): | -$25.20M as of Sep 30, 2023 |
Free cash flow (TTM): | -$110.37M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 3,846,772 as of Nov 6, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |